CTXR Stock Forecast: Citius Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.51
+2.63% on the day

The median 12-month analyst price target for Citius Pharmaceuticals, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 34 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$14.0M
Ticker Nerd rank
34/ 100
Median analyst target
$4.00
Analysts covering
1
Revenue$1.5M
Operating income−$10.0M
Net income−$11.9M
Free cash flow−$8.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.6%
1M
+22.1%
YTD
−34.3%
1Y
−48.5%
From 52W high
−64.6%
From 52W low
+37.5%
$0.37
$1.44
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Citius Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
34/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
65
Revisions
57
Growth
40
Volatility
40
Accruals
35
Value
32
Momentum
28
Issuance
11

Quality (65): The business earns solid, repeatable profits on what it owns.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CTXR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTXR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26CTXRHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$4.00
Low
$4.00
Median
$4.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 May 2026HC Wainwright & Co.AssumesBuy$4.00
11 Mar 2026D. Boral CapitalMaintainsBuy—
4 Dec 2025D. Boral CapitalMaintainsBuy—
13 Aug 2025D. Boral CapitalMaintainsBuy—
30 June 2025D. Boral CapitalMaintainsBuy—
10 June 2025D. Boral CapitalMaintainsBuy—
9 June 2025D. Boral CapitalMaintainsBuy—
23 May 2025Maxim GroupDowngradeHold—
15 May 2025D. Boral CapitalMaintainsBuy—
18 Feb 2025D. Boral CapitalMaintainsBuy—
7 Jan 2025D. Boral CapitalMaintainsBuy—
30 Dec 2024D. Boral CapitalUpgradeBuy—
22 Nov 2024D. Boral CapitalDowngradeHold—
12 Nov 2024HC Wainwright & Co.ReiteratesBuy—
11 Nov 2024D. Boral CapitalMaintainsBuy—
19 Aug 2024EF HuttonMaintainsBuy—
8 Aug 2024EF HuttonMaintainsBuy—
5 Aug 2024EF HuttonMaintainsBuy—
15 July 2024EF HuttonInitiatesBuy—
31 May 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CTXR.

Market Radar

This page is one stock. Monday covers all of them.

CTXR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CTXR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Citius Pharmaceuticals, Inc. returned −48.5% against +6.9% for the S&P 500, dividends included.

CTXR vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26CTXRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CTXR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
2.0×

Cheaper than 49% of US stocks

Price / book
0.2×

Cheaper than 94% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−10.4%

Higher than 16% of US stocks

Earnings growth (YoY)
—
Gross margin
67.1%

Higher than 80% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−81.1%

Higher than 16% of US stocks

Return on assets
−26.6%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Citius Pharmaceuticals, Inc. has a market value of $14.0M and an enterprise value of $13.4M.

  • Revenue in the twelve months to 30 June 2026: $7.1M.

  • Net income over the same four quarters: −$58.2M, a −818.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$34.9M.

  • Shares outstanding: 27.5M.

  • Citius Pharmaceuticals, Inc. employs 23 people — $309K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

CTXR and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CTXRCitius Pharmaceuticals, Inc.$14.0M34
BYSIBeyondSpring, Inc.$13.7M11
ACTUActuate Therapeutics, Inc.$13.6M39
NCELNewCelX Ltd.$13.6M4
PLURPluri, Inc.$13.5M17
ESLAEstrella Immunopharma, Inc.$13.5M26
ABOSAcumen Pharmaceuticals, Inc.$13.5M42

Take a look at CTXR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Citius Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CTXR

What is the CTXR stock price forecast for 2026-2027?

The median 12-month analyst price target for Citius Pharmaceuticals, Inc. is $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTXR stock a buy right now?

Of the 1 analyst covering Citius Pharmaceuticals, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Citius Pharmaceuticals, Inc. 34 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTXR?

As at 21 Nov 2026, Citius Pharmaceuticals, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (65 of 100).

Will CTXR stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $4, and Ticker Nerd's factor model ranks Citius Pharmaceuticals, Inc. 34 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTXR stock forecast for 2030?

No analyst covering Citius Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTXR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has CTXR stock performed over the past year?

Citius Pharmaceuticals, Inc. returned -48.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Citius Pharmaceuticals, Inc. do?

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing critical care products for specialized medical needs. Citius Pharmaceuticals, Inc. concentrates on areas such as oncology, anti-infectives, adjunct cancer care, prescription products, and stem cell therapy.

Company

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing critical care products for specialized medical needs. Citius Pharmaceuticals, Inc. concentrates on areas such as oncology, anti-infectives, adjunct cancer care, prescription products, and stem cell therapy. Its current portfolio includes LYMPHIR, a targeted immunotherapy for cutaneous T-cell lymphoma, along with late-stage programs such as Mino-Lok for catheter-related bloodstream infections and Halo-Lido for hemorrhoid relief. The company also advances other product candidates aimed at hospital, oncology, and acute-care settings. Headquartered in Cranford, New Jersey, Citius Pharmaceuticals, Inc. plays a role in bringing niche therapies and treatment options to patients and healthcare providers in markets with unmet clinical needs.

CEO Mr. Leonard L. Mazur · 23 employees · United States · https://citiuspharma.com